Valeant Pharma authorizes $500M securities buyback
Valeant Pharmaceuticals International said Tuesday its board authorized a $500 million repurchase of stock, convertible debt or senior notes.
Valeant said it had bought back $415 million in securities under previous authorizations, and can still buy another $85 million under that plan. The authorization lasts until March 2013.
In morning trading, Valeant shares rose 27 cents to $42.38. The stock has been trading at annual highs and peaked at a 52-week high of $42.65.